Skip to content

Author

Mark R. Walter

We have 2 of 12 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Jan 2026

A bireporter recombinant SARS-CoV-2 Omicron BA.5 for in vitro and in vivo studies

The results demonstrate the feasibility of using rBA.5 ZsG-Nluc to track viral infections and identify prophylactics and therapeutics against recent SARS-CoV-2 VoCs in vitro, ex vivo, and in vivo.

Esteban M. Castro, Ramya S. Barre, C. Ye et al. · 0 citations
Open access Aug 2026

Emergence of neutralizing RBD antibodies following Omicron infection with limited activity against ancestral SARS-CoV-2

Analysis suggests mAbs generically defined as class 1/4 mAbs may be separated into two classes, like Class 1/4 mAbs, and class 4/1 mAbs that make extensive interactions with the class-4 epitope and limited contacts with the class-1 knob498-596.

M. Piepenbrink, Yao Ma, Simran Panjwani et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.